Juan Dizon
A5082201074- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Immunotherapy and Immune Responses
- Long-Term Effects of COVID-19
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- vaccines and immunoinformatics approaches
- Animal Virus Infections Studies
- HIV/AIDS Research and Interventions
- SARS-CoV-2 detection and testing
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Viral Infections and Immunology Research
- Bacillus and Francisella bacterial research
Rockefeller University
2017-2022
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to infection of millions people and claimed hundreds thousands lives. The entry virus into cells depends on receptor-binding domain (RBD) spike (S) protein SARS-CoV-2. Although there is currently no vaccine, it likely that antibodies will be essential for protection. However, little known about human antibody response SARS-CoV-21–5. Here we report 149...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 deaths to date. Infection associated with the development of variable levels antibodies neutralizing activity, which can protect against infection in animal models1,2. Antibody decrease time, but, our knowledge, nature quality memory B cells that would be required produce upon reinfection not been examined. Here we report on humoral response a cohort 87 assessed at...
Here we report on the antibody and memory B cell responses of a cohort 20 volunteers who received Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-21-4. Eight weeks after second injection vaccine, showed high levels IgM IgG anti-SARS-CoV-2 spike protein (S) receptor-binding-domain (RBD) binding titre. Moreover, plasma neutralizing activity relative numbers RBD-specific cells vaccinated were equivalent to those individuals had recovered from natural infection5,6....
Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B cell responses that continue to evolve for at least a year. During time, memory cells express increasingly broad and potent antibodies are resistant mutations found in variants of concern 1 . As result, vaccination disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines high levels plasma neutralizing activity against all tested 1,2 Here we examine evolution five months...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 deaths to date. Infection associated with development of variable levels antibodies neutralizing activity that can protect against infection in animal models. Antibody decrease time, but the nature quality memory B cells would be called upon produce re-infection not been examined. Here we report on humoral response a cohort 87 assessed at 1.3 6.2 months after...
To date severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 100 million individuals resulting in two deaths. Many vaccines are being deployed to prevent coronavirus disease 2019 (COVID-19) including novel mRNA-based 1,2 . These elicit neutralizing antibodies and appear be safe effective, but the precise nature of elicited is not known 3–6 Here we report on antibody memory B cell responses a cohort 20 volunteers who received either Moderna (mRNA-1273) or...
Abstract During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds thousands lives. Virus entry into cells depends on receptor binding domain (RBD) spike protein (S). Although there is no vaccine, it likely that antibodies will be essential for protection. However, little known about human antibody response to 1–5 . Here we report 149 convalescent individuals. Plasmas collected an average 39 days after onset symptoms had variable half-maximal neutralizing...
SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that contribute to better clinical outcomes. The receptor-binding domain (RBD) and the N-terminal (NTD) of spike trimer (S) constitute two major targets for antibodies. Here, we use NTD-specific probes capture anti-NTD memory B cells in a longitudinal cohort infected individuals, some whom were vaccinated. We found 6 complementation groups 58% targeted epitopes outside NTD supersite, neutralized either Gamma...
Abstract Feedback inhibition of humoral immunity by antibodies was first documented in 1909 1 . Subsequent studies showed that, depending on the context, can enhance or inhibit immune responses 2,3 However, little is known about how pre-existing influence development memory B cells. Here we examined cell response individuals who received two high-affinity anti-SARS-CoV-2 monoclonal and subsequently doses an mRNA vaccine 4–8 We found that recipients produced antigen-binding neutralizing...
A clinical trial was performed to evaluate 3BNC117, a potent anti–HIV-1 antibody, in infected individuals during suppressive antiretroviral therapy and subsequent analytical treatment interruption (ATI). The circulating reservoir evaluated by quantitative qualitative viral outgrowth assay (Q2VOA) at entry after 6 mo. There were no significant changes the size of before ATI, composition clones varied manner that did not correlate with 3BNC117 sensitivity. binding site amino acid variants...
Individuals who receive a third mRNA vaccine dose show enhanced protection against severe COVID-19, but little is known about the impact of breakthrough infections on memory responses. Here, we examine antibodies that develop after or fourth antigenic exposure by Delta Omicron BA.1 infection, respectively. A to antigen increases number B cells produce with comparable potency and breadth dose. infection increased variant-specific plasma antibody cell However, did not increase overall...
Recently discovered broadly neutralizing antibodies (bNAbs) against HIV-1 demonstrate extensive breadth and potency diverse strains represent a promising approach for the treatment prevention of infection. The these have primarily been evaluated by using panels Env-pseudotyped viruses produced in 293T cells expressing molecularly cloned Env proteins. Here we report on ability five bNAbs currently clinical development to neutralize circulating primary isolates derived from peripheral blood...
The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale pace. As result, current regimens comprise diverse vaccine modalities, immunogen combinations, dosing intervals. Here, we compare vaccine-specific antibody memory B cell responses following two-dose mRNA, single-dose Ad26.COV.2S, ChAdOx1, or combination ChAdOx1/mRNA vaccination. Plasma-neutralizing activity, as well magnitude, clonal composition, maturation...
The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either the two available mRNA vaccines. In addition, has been less effective severe disease during Omicron surge. Here, we examined memory B cell response to vaccination. Compared with vaccines, recipients had significantly numbers RBD-specific cells 1.5 or 6 mo after Despite numbers, overall quality responses appears be similar,...
Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces B-cell responses that continue to evolve for at least one year. During time, memory B cells express increasingly broad and potent antibodies are resistant mutations found in variants of concern 1 . As a result, vaccination disease 2019 (COVID-19) convalescent individuals with currently available mRNA vaccines high levels plasma neutralizing activity against all tested 1, Here, we examine cell evolution 5...
Feedback inhibition of humoral immunity by antibodies was initially documented in guinea pigs Theobald Smith 1909, who showed that passive administration excess anti-Diphtheria toxin inhibited immune responses1. Subsequent work can enhance or inhibit responses depending on antibody isotype, affinity, the physical nature antigen, and engagement immunoglobulin (Fc) complement (C') receptors2,3. However, little is known about how pre-existing might influence subsequent development memory B...
SARS-CoV-2 infection or vaccination produces neutralizing antibody responses that contribute to better clinical outcomes. The receptor binding domain (RBD) and the N-terminal (NTD) of spike trimer (S) constitute two major targets for system. Neutralizing antibodies targeting RBD bind several different sites on this domain. In contrast, most NTD characterized date a single supersite, however these were obtained by methods not specific. Here we use specific probes focus anti-NTD memory B cells...
Abstract Individuals that receive a 3 rd mRNA vaccine dose show enhanced protection against severe COVID19 but little is known about the impact of breakthrough infections on memory responses. Here, we examine antibodies develop after or 4 th antigenic exposure by Delta Omicron BA.1 infection, respectively. A to antigen increases number B cells produce with comparable potency and breadth dose. infection increased variant specific plasma antibody cell However, did not increase overall...
Abstract A clinical trial was performed to evaluate 3BNC117, a potent anti_HIV_1 antibody, in infected individuals during suppressive antiretroviral therapy (ART) and subsequent analytical treatment interruption (ATI). The circulating reservoir evaluated by quantitative qualitative outgrowth assay (Q 2 VOA) at entry after 6 months, prior ATI. Although there were no significant changes the size of reservoir, composition clones varied over 6_month period before manner that did not correlate...
Abstract The single dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either the available mRNA vaccines. In addition, has been less effective severe disease during Omicron surge. Here, we examined memory B cell response to vaccination. Compared vaccines, recipients had significantly numbers RBD-specific cells 1.5 or 6 months after Memory elicited by both types show comparable potency...
Abstract The SARS-CoV-2 pandemic prompted a global vaccination effort and the development of numerous COVID-19 vaccines at an unprecedented scale pace. As result, current COVID- 19 regimens comprise diverse vaccine modalities, immunogen combinations dosing intervals. Here, we compare vaccine-specific antibody memory B cell responses following two-dose mRNA, single-dose Ad26.COV2.S ChAdOx1 or combination ChAdOx1/mRNA vaccination. Plasma neutralizing activity as well magnitude, clonal...